Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Saarland University, Building 46, D-66421 Homburg (Saar), Germany.
Drug Metab Dispos. 2011 Nov;39(11):1998-2002. doi: 10.1124/dmd.111.041129. Epub 2011 Jul 27.
Different pharmacokinetic properties are known for the two enantiomers of the entactogen 3,4-methylendioxy-methamphetamine (MDMA), most likely due to enantioselective metabolism. The aim of the present work was 1) the investigation of the main sulfotransferases (SULT) isoenzymes involved in the sulfation of the main MDMA phase I metabolites 3,4-dihydroxymethamphetamine (DHMA) and 4-hydroxy-3-methoxymethamphetamine (HMMA) and 2) the evaluation of a possible enantioselectivity of this phase II metabolic step. Therefore, racemic DHMA and HMMA were incubated with heterologously expressed SULTs, and quantification of the sulfates by liquid chromatography-high-resolution mass spectrometry was conducted. Because separation of DHMA and HMMA sulfate could not be achieved by liquid chromatography, enantioselective kinetic parameters were determined using the substrate-depletion approach with enantioselective quantification of substrate consumption by gas chromatography-negative ion chemical ionization mass spectrometry. SULT1A1 and SULT1A3 catalyzed sulfation of DHMA, and SULT1A3 and SULT1E1 catalyzed sulfation of HMMA. SULT1A1 and SULT1E1 revealed classic Michaelis-Menten kinetics, whereas SULT1A3 kinetics showed deviation from the typical Michaelis-Menten kinetics, resulting in a concentration-dependent self-inhibition. SULT1A3 showed the highest affinity and capacity of the SULT isoforms. Marked enantioselectivity could be observed for S-DHMA sulfation by SULT1A3 and in human liver cytosol, whereas no differences were observed for HMMA sulfation. Finally, comparison of K(m) and V(max) values calculated using achiral product formation and chiral substrate depletion showed good correlation within 2-fold of each other. In conclusion, preferences for S-enantiomers were observed for DHMA sulfation, but not for HMMA sulfation.
手性药物 3,4-亚甲二氧基甲基苯丙胺(MDMA)的两种对映异构体具有不同的药代动力学特性,这很可能是由于对映选择性代谢所致。本研究的目的是:1)研究主要磺基转移酶(SULT)同工酶在 MDMA 主要 I 相代谢物 3,4-二羟甲基苯丙胺(DHMA)和 4-羟基-3-甲氧基甲基苯丙胺(HMMA)磺化中的作用;2)评估此 II 相代谢步骤是否具有对映选择性。因此,将外消旋 DHMA 和 HMMA 与异源表达的 SULT 孵育,并通过液相色谱-高分辨率质谱法对硫酸盐进行定量。由于无法通过液相色谱法分离 DHMA 和 HMMA 硫酸盐,因此通过底物耗竭法测定对映选择性动力学参数,通过气相色谱-负化学电离质谱法对底物消耗进行对映选择性定量。SULT1A1 和 SULT1A3 催化 DHMA 磺化,SULT1A3 和 SULT1E1 催化 HMMA 磺化。SULT1A1 和 SULT1E1 显示出经典的米氏动力学,而 SULT1A3 动力学显示出偏离典型米氏动力学的情况,导致浓度依赖性的自抑制。SULT1A3 显示出 SULT 同工酶中最高的亲和力和容量。在 SULT1A3 和人肝胞质中,观察到 S-DHMA 磺化的显著对映选择性,而 HMMA 磺化则没有观察到差异。最后,使用非手性产物形成和手性底物耗竭计算的 K(m)和 V(max)值进行比较,在彼此 2 倍的范围内显示出良好的相关性。总之,观察到对映体 S-DHMA 磺化的偏爱,但对 HMMA 磺化没有偏爱。